Ledyard National Bank Grows Holdings in Eli Lilly and Company (NYSE:LLY)

Ledyard National Bank grew its stake in Eli Lilly and Company (NYSE:LLY) by 0.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,998 shares of the company’s stock after purchasing an additional 22 shares during the period. Ledyard National Bank’s holdings in Eli Lilly and Company were worth $2,331,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. JGP Wealth Management LLC grew its holdings in Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after buying an additional 16 shares during the last quarter. Patton Albertson Miller Group LLC raised its holdings in Eli Lilly and Company by 2.8% in the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after acquiring an additional 17 shares during the last quarter. Valley Wealth Managers Inc. boosted its holdings in shares of Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after purchasing an additional 17 shares during the last quarter. Sandy Cove Advisors LLC lifted its position in Eli Lilly and Company by 0.8% during the fourth quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock worth $1,307,000 after buying an additional 17 shares during the period. Finally, Lathrop Investment Management Corp grew its holdings in Eli Lilly and Company by 1.2% in the 3rd quarter. Lathrop Investment Management Corp now owns 1,476 shares of the company’s stock valued at $793,000 after buying an additional 18 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $3.82 during midday trading on Monday, reaching $737.33. 2,726,536 shares of the company traded hands, compared to its average volume of 3,017,770. The firm has a market capitalization of $700.58 billion, a price-to-earnings ratio of 127.13, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The company has a fifty day moving average price of $760.89 and a 200 day moving average price of $668.00. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a twelve month low of $392.26 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the company earned $2.09 earnings per share. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, analysts expect that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on LLY. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a research report on Monday, April 15th. The Goldman Sachs Group raised their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Finally, Truist Financial restated a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.